<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178124</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-002</org_study_id>
    <nct_id>NCT02178124</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icure Pharmaceutical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icure Pharmaceutical Inc.</source>
  <brief_summary>
    <textblock>
      Study of the Safety, tolerability and pharmacokinetics with multiple doses of donepezil patch
      in healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability evaluation</measure>
    <time_frame>patch : -1d~33d, oral : -1~11d</time_frame>
    <description>evaluation item
adverse event
electrocardiographie
vital sign
physical examination
urine, blood test
skin irritation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics characteristic evaluation</measure>
    <time_frame>patch: -1~25d, oral -1~11d</time_frame>
    <description>cohort 1
1d 0h (pre-dose), 4h, 8h, 12h, 24h (2d), 48h (3d), 72h (4d), 144h (7d), 216h (10d), 288h (13d, last dose start), 292h, 296h, 300h, 312h (14d), 336h (15d), 360h (16d, patch removal), 362h, 364h, 368h, 372h, 384h (17d), 408h (18d), 432h (19d), 480h (21d), 528h (23d), 576h (25d)
cohort 2 1 period Oral Donepezil
1d 0h (pre-dose), 0.5h, 1h, 1.5h, 2h, 3h, 4h, 8h, 12h, 24h (2d), 48h (3d), 96h (5d), 144h (7d), 192h (9d), 240h (11d)
period 2 Donepezil Patch: same cohort1
evaluation item : donepezil conc.
evaluation variable patch : AUCτ,ss, Cmax,ss, t1/2β, AI (accumulation index), Cav,ss oral : AUClast, AUC0-∞, Cmax, tmax, t1/2β, CL/F</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>dosage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug : 9 people(87.5mg/25cm2) placebo : 3 people(0mg/25cm2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dosage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage2 period 1 : oral administration drug : 12 people(10mg)
dosage 2 period 2: transdermal administration drug : 9 people(175mg/50cm2) placebo : 3 people(0mg/50cm2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <arm_group_label>dosage 1</arm_group_label>
    <arm_group_label>dosage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>dosage 1</arm_group_label>
    <arm_group_label>dosage 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI : more than 19 ㎏/㎡, less than 27 ㎏/㎡

          -  Systolic blood pressure : more than 90, less than 140 (mmHg)

          -  Diastolic blood pressure : more than 60, less than 100 (mmHg)

        Exclusion Criteria:

          -  Evidence of clinically significant, severe, active, or unstable gastrointestinal,
             renal,hepatic, respiratory, hematological, endocrine, or cardiovascular system
             disease.

          -  A history of skin disease or skin graft

          -  Hypersensitivity to donepezil or piperidine derivatives or any of the excipients.

          -  A known or suspected history of drug or alcohol dependency or abuse

          -  Patients who have participated in another clinical study within 60 days.

          -  Whole blood within 60 days, apheresis within 30 days, transfusion within 30 days

          -  Heavy alcohol intake(more than 21 units/week)

          -  Heavy smoker(more than 10 cigarette/day)

          -  Abnormal clinical laboratory values which are judged clinically significant by the
             investigator.

          -  Any condition that would make the patient or the caregiver, in the opinion of the
             investigator, unsuitable for the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2014</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

